男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Trials show China's intranasal COVID-19 vaccine effective

Xinhua | Updated: 2022-06-01 15:18
Share
Share - WeChat

BEIJING -- A China-developed intranasal vaccine against COVID-19 has shown to be safe and effective in early-stage human trials, according to a new study published in the journal The Lancet Respiratory Medicine.

Compared with currently available COVID-19 vaccines that are administered by intramuscular injection, the new drug, coded dNS1-RBD, is a two-dose, live-attenuated influenza vaccine given through the nose. It was jointly developed by Xiamen University, the University of Hong Kong and Beijing Wantai Biological Pharmacy Enterprise.

Researchers conducted phase-1 and phase-2 trials at hospitals in East China's Jiangsu province from September 2020 to July 2021. More than 1,000 healthy adults aged between 18 and 86 were enrolled in the trials, which were randomized, double-blind and placebo-controlled.

According to the study, one month after the second dose, the immune responses were observed in the vaccine recipients. The proportion of responders was 40 percent, which was, significantly higher than that in the placebo group.

The study also highlighted that the needle-free vaccine was well tolerated by all participants. Its efficacy in older adults (aged 60 and above) was similar to that in younger recipients (aged between 18 and 59).

Most adverse reactions were mild or moderate flu-like symptoms, such as rhinorrhoea, fever, and fatigue. No serious adverse events were reported after vaccination.

The phase-3 trials with more participants are currently underway in the Philippines, South Africa, Vietnam and Colombia to test the efficacy of the Chinese vaccine, said the study.

The vaccine candidate is introduced to a cold-adapted influenza strain, into which receptor-binding domain genes from SARS-CoV-2 are inserted by gene reassortment.

In the preclinical study, the vaccine showed rapid, long-lasting, and broad protection against the SARS-CoV-2 challenge in mice. According to vaccine makers, nine months after two doses of dNS1-RBD, the protective effect against the SARS-CoV-2 beta variant remained as good as that against the original strain of the virus.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 和林格尔县| 河津市| 广饶县| 中方县| 赞皇县| 原阳县| 博罗县| 元朗区| 二连浩特市| 城固县| 望奎县| 大同市| 蓬溪县| 禄丰县| 永州市| 成都市| 北流市| 龙里县| 陆丰市| 瑞丽市| 朝阳区| 桂平市| 和顺县| 恩施市| 肇东市| 阿城市| 奉节县| 拉萨市| 仁化县| 乐业县| 神农架林区| 金门县| 榆中县| 随州市| 云霄县| 龙泉市| 广灵县| 谢通门县| 达拉特旗| 南岸区| 喀什市|